Psoriatic arthritis

psoriatic-arthritis · society: ACR/NPF

← back to Rheumatology

Summary

First joint ACR/NPF guideline for treating active psoriatic arthritis (PsA), using GRADE methodology to address pharmacologic and nonpharmacologic management in treatment-naive patients, those failing prior therapy, and special populations (axial disease, enthesitis, IBD, diabetes, recurrent infections). Notably recommends TNF inhibitor biologics as first-line over oral small molecules (OSMs) in most treatment-naive patients with active PsA—a departure from EULAR/GRAPPA which preferred OSMs first. Endorses a treat-to-target strategy, smoking cessation, and vaccination considerations around biologic initiation. 94% of recommendations are conditional based on low/very-low-quality evidence.

Current guideline: ACR/NPF 2018 Psoriatic Arthritis Guideline · download Anki sub-deck

Versions

• 2018 · ACR/NPF — ACR/NPF 2018 Psoriatic Arthritis Guideline
  • Read the guideline: html · pmc · Anki deck

---

Table of contents

• 2018 · ACR/NPF